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ABSTRACT 
Objective Macrophage activation by monosodium 
urate (MSU) and calcium pyrophosphate (CPP) 
crystals mediates an interleukin (IL)-1 �-de pendent 
inflammation during gout and pseudo-gout tiare, 
respectively. Since metabolic reprogramming of 
macrophages goes along with inflammatory responses 
dependently on stimuli and tissue environment, we 
aimed to decipher the role of glycolysis and oxidative 
phosphorylation in the IL-l !3-induced microcrystal 
response. 
Methods Briefly, an in vitro study (metabolomics 
and real-time extracellular flux analysis) on MSU and 
CPP crystal-stimulated macrophages was performed to 
demonstrate the metabolic phenotype of macrophages. 
Then, the role of aerobic glycolysis in IL -113 production 
was evaluated, as well in vitro as in vivo using 18F­
fluorodeoxyglucose positron emission tomography 
imaging and glucose uptake assay, and molecular 
approach of glucose transporter 1 (GLUT1) inhibition. 
Results We observed that MSU and CPP crystals 
led to a metabolic rewiring toward the aerobic 
glycolysis pathway explained by an increase in GLUT1 
plasma membrane expression and glucose uptake on 
macrophages. Also, neutrophils isolated from human 
synovial fluid during gout tiare expressed GLUT1 
at their plasma membrane more frequently than 
neutrophils isolated from bloodstream. Both glucose 
deprivation and treatment with either 2-deoxyglucose 
or GLUTl inhibitor suppressed crystal-induced NLRP3 
activation and IL-113 production, and microcrystal 
inflammation in vivo. 
Conclusion ln conclusion, we demonstrated that 
GLUT1-mediated glucose uptake is instrumental during 
the inflammatory IL -1 � response induced by MSU and 
CPP crystals. These findings open new therapeutic 
paths to modulate crystal-related inflammation. 
INTRODUCTION 
Monosodium urate (MSU) and monoclinic calcium 
pyrophosphate dihydrate (m-CPPD) crystals are 
responsible for gout and m-CPPD deposition 
diseases, respectively. Both crystals activate the 
innate immune system and induce recurrent and 
painful flares, which are interleukin (IL)-1 �- driven 
Key messages 
What is already known about this subject? 
► A switch of cell metabolism from oxidative
phosphorylation to aerobic glycolysis in order
to support energy demand is a hallmark of
inflammatory phenotype of macrophages
and multiple immune-mediated inflammatory
diseases such as cancer or autoimmune
diseases.
► Gout and pseudo-gout tiare depend on
monosodium urate (MSU) and calcium
pyrophosphate crystal-induced interleukin (IL)-
1 � production, respectively, by macrophages.
What does this study add? 
► MSU and monoclinic calàum pyrophosphate
dihydrate (m-CPPD) crystal stimulation leads to
a metabolic reprogramming of macrophages in
faveur of aerobic glycolysis.
► MSU and m-CPPD crystal-induced NLRP3
inflammasome activation and IL-113 production
by macrophages, as well as microcrystal­
mediated inflammation in vivo, rely on a
de novo glucose uptake through glucose
transporter 1 .
How might this impact on clinical practice or 
future developments? 
► This study demonstrated the key role of
inflammatory cell metabolism and glucose
availability in the inflammatory process
of microcrystal-related pathology. lt thus
highlights a potential new therapeutic path for
acute and chronic patients' arthritis care.
inflammations caused by macrophage-mediated 
neutrophil infiltt·ation and activation in joints.1 2 
IL-1� production is a two- step process which can 
both be activated by MSU and m-CPPD crys­
tals. The first step involves nuclear factor-KB 
and mitogen-activated protein kinase pathways,3 
leading to pro-IL-1� synthesis, and the second one 
relies on the nucleotide-binding oligomerisation 
domain (NOD)-like receptor family, pyrin (NLRP) 
domain-containing 3 inflammasome complex and 
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gives rise to the secretion of active IL-1β.1 Activated NLRP3 
stimulates speck formation of the adaptor protein apoptosis- 
associated speck- like containing a CARD (ASC) and recruits 
pro- caspase-1 into the NLRP3/ASC complex through homo-
typic domain–domain interactions.4 5 Assembly of pro- caspase-1 
within the NLRP3 inflammasome allows its autoproteolysis and 
the release of active caspase-1, which cleaves its substrates pro- 
IL-1β and pro- IL-18 into their mature forms.4 NLRP3- deficient 
macrophages are unable to produce mature IL-1β under MSU 
and m- CPPD crystal stimulation.1 3 Blocking IL-1β abrogates 
MSU- induced and m- CPPD- induced inflammation and consti-
tutes an efficient therapeutic option in gout flare.6 7 However, 
long- term inhibition of IL-1β may increase infection risk. Thus, 
understanding mechanisms of NLRP3 activation by MSU and 
m- CPPD crystals might offer a safer way to modulate IL-1β
effects.
NLRP3 can be activated through several mechanisms, 
including reprogramming of cell metabolism.8–11 First described 
in cancer cells, the so- called Warburg effect characterised by 
an increase in glucose uptake and aerobic glycolysis, along 
with a reduction of the mitochondrial respiration (oxidative 
phosphorylation (OXPHOS)), and an inhibition of tricarbox-
ylic acid (TCA) cycle plays a critical role in host defence and 
inflammation and is a metabolic hallmark of activated immune 
cells and proinflammatory macrophages.8–10 Thus, high concen-
trations of glucose increase IL-1β production through the 
NLRP3- dependent pathway, while inhibition of glycolysis with 
2- deoxyglucose (2- DG) suppresses IL-1β production by macro-
phages stimulated with the TLR-4 agonist lipopolysaccha-
ride (LPS) or ATP.12 13 LPS- induced glycolysis stimulates IL-1β
production through hexokinase (HK) 1, hypoxia- inducible
factor 1α (HIF-1α) and pyruvate kinase muscle (PKM) 2 activa-
tion, three molecules of the glycolysis pathway directly involved
in NLRP3 activation and IL-1β production.14–16 In parallel,
TLR4 activation induces TCA cycle alteration stimulating IL-1β
production through cytosolic accumulation of succinate, which
prevents degradation of HIF-1α by prolylhydroxylase enzyme.12
Stabilised HIF-1α then enhances the expression of genes
encoding IL-1β and proteins involved in glycolysis pathways,
such as glucose transporter 1 (GLUT1) and HK, which further
amplify glucose uptake and glycolysis.12 15 17 Interestingly,
glucose uptake quantified with 18F- fluorodeoxyglucose ([18F]-
FDG) positron emission tomography (PET) is increased in joints
with gout flare and in soft- tissue surrounding MSU or m- CPPD
crystal deposition, suggesting that glucose consumption plays an
important role in crystal- induced inflammation.18 19 Moreover,
the ketone body β-hydroxybutyrate produced during starvation
or low- carbohydrate ketogenic diet inhibits IL-1β production
Figure 1 Crystal- induced inflammation depends on glucose availability. Primed THP-1 cells were stimulated with either PBS or MSU or m- CPPD 
crystals. (A,B) IL-1β production was quantified by ELISA in supernatants of cell culture in the (A) absence or presence of glucose (n=9). Multiple t- test 
with false discovery rate (FDR) correction between +glucose and –glucose (*): #p<0.05, ##p<0.01, ###p<0.001. (B) In the absence (PBS) or presence of 
2- DG (20 mM, n=4). Data are presented in % of inhibition of IL-1β production compared with PBS (100%). Kruskal- Wallis test with FDR correction (*): 
*p<0.05, **p<0.01, ***p<0.001. (C,D) ASC speck formation was observed with confocal microscopy and quantified in cells cultured with medium
containing or not containing glucose. (C) Imaging representative of three independent experiments and (D) quantification of cells expressing at
least one speck complex (n=3). Multiple t- test with FDR correction between +glucose and –glucose (#): #p<0.05, ##p<0.01, ###p<0.001. (E–J) Mouse
air pouch model of microcrystal inflammation: IL-1β concentration (E), cell infiltration (F), proportion of neutrophils and macrophages (F,G) in the
air pouch lavages of mice injected by either PBS, MSU or m- CPPD crystals and treated with 2- DG or PBS (n=12/group); H&E staining of air pouch
membranes (I) and scoring of the inflammation (J) (n=5). Two- way analysis of variance test with FDR correction (#): #p<0.05, ##p<0.01, ###p<0.001. 
2- DG, 2- deoxyglucose; ASC, apoptosis- associated speck- like containing a CARD; IL, interleukin; m- CPPD, monoclinic calcium pyrophosphate dihydrate; 
MSU, monosodium urate; NS, not significant.
by macrophages and inflammation in a mouse gout model.20 21 
Nevertheless, whether macrophage metabolism reprogramming 
is involved in MSU and m- CPPD crystal- induced IL-1β produc-
tion remains unknown.
In this study, we aimed to assess the metabolic phenotype 
of macrophages and the role of glucose uptake in the NLRP3- 
dependent IL-1β production in response to MSU and m- CPPD 
crystals. We observed that MSU and m- CPPD crystals induced 
metabolic modifications in macrophages towards an increase in 
glycolytic activity. Upregulation of glycolysis corroborated with 
a de novo glucose uptake mediated by the glucose transporter 
(GLUT) GLUT1, in response to microcrystals. Interestingly, 
glucose deprivation or glycolysis inhibition by knock- down of 
GLUT1 prevented ASC oligomerisation (NLRP3 activation) and 
IL-1β secretion induced by both crystals. Moreover, both inhi-
bition of GLUT1 and glycolysis inhibition by 2- DG decreased 
MSU and m- CPPD crystal- induced inflammation in an in vivo 
mouse model. Finally, in patients with gout flare, neutrophils 
isolated from the inflamed joint expressed more frequently 
GLUT1 at their surface membrane than circulating neutrophils, 
which highlights a promising specific approach for GLUT1 
targeting as a gout flare therapy.
RESULTS
MSU and m-CPPD crystal-induced inflammation depends on 
glucose metabolism
To assess the role of glucose metabolism in crystal- induced 
inflammation, we stimulated cells with media containing 
increasing concentrations of glucose (0–4 g/L) or supplemented 
with the glucose analogue 2- DG, an inhibitor of glycolysis. 
Both glucose deprivation and glycolysis inhibition drastically 
decreased IL-1β production by primed THP-1 cells or mouse 
bone marrow- derived macrophages (BMDMs) stimulated by 
either MSU or m- CPPD crystals (glucose deprivation decreased 
by more than 90% the crystal- induced IL-1β production by 
BMDMs) (figure 1A,B; online supplementary figure S1A,B). In 
contrary, increasing concentrations of glucose- enhanced IL-1β 
production (see online supplementary figure 1C). Neverthe-
less, prostaglandin E2 and CXCL1 production, two proin-
flammatory mediators involved in crystal inflammation, did 
not depend on glucose availability (see online supplementary 
figure S1E–F). Suppression of IL-1β production is secondary 
to the inhibition of NLRP3 inflammasome.1 3 Here, we demon-
strated that glucose deprivation suppressed ASC oligomerisa-
tion and speck formation induced by either MSU or m- CPPD 
crystals (figure 1C,D). We confirmed, in vivo, the central 
role of glycolysis and observed that mice treated with 2- DG 
displayed mild inflammatory response compared to untreated 
mice 6 hours after MSU or m- CPPD crystal stimulation. 
Indeed, 2- DG abrogated crystal- induced IL-1β production and 
prevented crystal- induced neutrophil infiltration assessed in 
the air pouch lavages (figure 1E–H). Histology analysis of air 
pouch membranes after H&E staining further evidenced that 
glycolysis inhibition suppressed neutrophil infiltration with a 
major decrease in inflammation score in mice treated by 2- DG 
(figure 1I,J).
Figure 2 MSU and m- CPPD crystals induce metabolic changes in the glycolysis pathway and the TCA cycle. (A–E) Metabolomics analysis was 
performed by mass spectrometry in primed THP-1 cells treated by either PBS, MSU or m- CPPD crystals. (A) Heatmap analysis and (B,C) principal 
component analysis of MSU and m- CPPD crystals versus PBS (n=10). Relative quantification (ratio of MSU or m- CPPD to PBS) of the different 
metabolites related to glycolysis (D) and Krebs cycle or OXPHOS (E). Kruskal- Wallis test with FDR correction (*): *p<0.05, **p<0.01, ***p<0.001. 
(F–H) Real- time extracellular flux analysis on LPS- primed BMDMs stimulated with either MSU or m- CPPD. (F) Time course of real- time changes in the 
ECAR after Glycolysis Stress Assay (n=6). (G) Time course of real- time changes in the OCR after Cell Mito Stress Assay (n=4). (H) Mean of basal ECAR 
(ratio of crystals over PBS). (I) Glycolysis Stress Assay (n=6): each rate was determined according to the SeaHorse Agilent Guide and described in the 
Materials and methods section. Kruskal- Wallis test with FDR correction (*): *p<0.05, **p<0.01, ***p<0.001. 2- DG, 2- deoxyglucose; BMDM, bone 
marrow- derived macrophage; DHAP, dihydroxyacetone phosphate; ECAR, extracellular acidification rate; FCPP, carbonyl cyanide-4- (trifluoromethoxy) 
phenylhydrazone; LPS, lipopolysaccharide; m- CPPD, monoclinic calcium pyrophosphate dihydrate; MSU, monosodium urate; NS, not significant; OCR, 
oxygen consumption rate; OXPHOS, oxidative phosphorylation; PEP, phosphoenolpyruvate; TCA, tricarboxylic acid.
MSU and m-CPPD crystals induce modifications in the 
glycolysis and TCA cycle pathways
To better understand the involvement of glucose and cell 
metabolism in the microcrystal inflammatory response, we 
performed a metabolomics study and observed in partial least 
squares discriminant analysis that cells stimulated by either 
MSU or m- CPPD crystals had robust distinct metabolic profiles 
without overlap components compared with unstimulated 
cells. Metabolomics data are available in online supplementary 
table S1. Specifically, we observed modifications of the abun-
dance of multiple metabolites (figure 2A–C). Crystals induced 
perturbation of multiple metabolic pathways, including amino 
acids and glucose metabolism (see online supplementary figure 
S2). We observed modifications in both glycolysis pathway and 
TCA cycle with a slight increase of fructose-6 phosphate and 
a strong decrease of phosphoenolpyruvate, α-ketoglutarate 
and malate (figure 2D,E). Beside glycolysis and TCA cycle 
components, there was also a decrease of glutamate and gluta-
mine, two amino acids able to refuel the Krebs cycle in the 
absence of pyruvate.22 23 Interestingly, the intracellular ATP 
was very low in crystal- stimulated cells, suggesting either an 
alteration of its production or an increased turnover. Then, we 
evaluated whether these crystals also modulated the expres-
sion of genes encoding enzymes or transporters involved in 
the glycolysis pathway and Krebs cycle. We did observe vari-
ations in expression of genes encoding HK-2, mitochondrial 
pyruvate carrier 1 and 2, monocarboxylate transporter 4, 
pyruvate dehydrogenase phosphatase 2, isocitrate dehydro-
genase 1 and 2, and pyruvate dehydrogenase kinase 2 and 3 
(see online supplementary figure S3A–D). Altogether, these 
results suggested that crystals altered glycolytic activity and 
mitochondrial function. We assessed this hypothesis with 
Seahorse experiments that permit analysis of real- time changes 
in the extracellular acidification rate (ECAR) (figure 2F) and 
oxygen consumption rate (OCR) (figure 2G), as surrogates 
of glycolysis and mitochondrial respiration, respectively. We 
observed that only MSU crystals increased macrophage basal 
glycolysis (figure 2H), glycolytic rate and glycolytic activity 
(figure 2I) while both MSU and m- CPPD crystals did not affect 
the OXPHOS (figure 2G; online supplementary figure S3E,F). 
Analysis of OCR suggested that MSU crystals increased only 
non- mitochondrial oxygen consumption (see online supple-
mentary figure S3F).
MSU and m-CPPD crystals increase glucose uptake associated 
with GLUT1 expression at the cell surface
As crystal- induced IL-1β production relied on glucose avail-
ability, we quantified the variation of glucose concentrations 
in cell culture media. By doing this, we observed that glucose 
concentrations were significantly lower in culture media of 
macrophages stimulated by either MSU or m- CPPD crystals than 
in culture media of unstimulated cells (figure 3A). Then, we 
confirmed the de novo glucose uptake by showing that MSU and 
m- CPPD crystals enhanced the intracellular level of radiolabelled 
[18F]-FDG by 152% and 148%, respectively (figure 3B). Glucose
uptake has been reported in gouty joint flare in patients18 19;
we reproduced this observation in the air pouch model using
Figure 3 Crystal- induced inflammation is associated with an increase in glucose uptake. (A) Extracellular glucose concentration in cell culture media 
was quantified 6 hours after crystal stimulation (n=5). (B) [18F]-fluorodeoxyglucose ([18F]-FDG) was quantified in cell pellets to assess glucose uptake 
after 1 hour of stimulation by either MSU or m- CPPD crystals (n=8). (C–E) Glucose uptake was quantified in air pouch (arrow) model using [18F]-FDG 
PET/CT. (C) Imaging representative of 6 mice; (D) SUVmax of air pouch; and (E) proportion of injected [
18F]-FDG dose detected in the air pouch (n=6
mice per group). (F) Ratio of [18F]-FDG per weight (g) of ex vivo isolated air pouch membranes. Kruskal- Wallis test with FDR correction (*): *p<0.05, 
**p<0.01, ***p<0.001. (G) Correlation between IL-1β concentration (pg/mL) in the air pouch and the [18F]-FDG quantification (% dose/g) in the cell 
infiltrate, Spearman test. [18F]-FDG, 18F- fluorodeoxyglucose; IL, interleukin; m- CPPD, monoclinic calcium pyrophosphate dihydrate; MSU, monosodium 
urate; SUVmax, maximum standardised uptake value.
[18F]-FDG. By PET/CT imaging, glucose uptake in response to 
MSU and m- CPPD crystals was evidenced by a higher labelling 
of the air pouch where crystals were injected, as well as higher 
maximum standardised uptake value (SUVmax) and ratio of radio-
labelled tracer found in air pouch compared with air pouch 
injected by saline solution (figure 3C–E). Moreover, after in vivo 
acquisition, quantification of the radiotracer showed that the 
level of [18F]-FDG was higher in air pouch membranes isolated 
from crystal- stimulated mice than from saline- stimulated mice 
(figure 3F), which was strongly correlated with IL-1β production 
in the air pouch (figure 3G).
Glucose enters the cells through GLUTs that belong to solute 
carrier family 2 (SCL2A), which encompasses 14 members. 
SLC2A proteins are overexpressed in tumour cells, and SLC2A1 
(GLUT1) is rapidly upregulated in inflammatory macrophages 
and contributes to glycolytic phenotype.24 GLUT6 has been 
previously reported as not being involved in glucose uptake and 
glycolysis25; therefore, we focused on GLUT1 expression. We 
first showed that both MSU and m- CPPD crystal stimulation 
in vitro upregulated the GLUT1 gene expression on BMDMs 
(see online supplementary figure S4B) and the GLUT1 protein 
expression on THP-1 cells (figure 4A–D; see also figure 5A). By 
confocal microscopy, we observed that microcrystals induced 
a higher expression of GLUT1 at the cell plasma membrane 
compared with unstimulated cells (figure 4A,B). Moreover, the 
analysis by flow cytometry showed that both crystals, as well 
as the NLRP3 activator LPS, induced an increase in mean of 
GLUT1 expression intensity at the cell surface (figure 4C,D). 
The increased GLUT1 expression in response to crystals was 
confirmed in vivo (figure 4E–G). First, we observed by immu-
nofluorescence an increased expression of GLUT1 in the air 
pouch membrane (figure 4E). Second, the infiltrated cells into 
the air pouch expressed a higher level of GLUT1 messenger 
RNA (mRNA) (figure 4F) after crystal injection compared with 
saline injection, and between 50% and 70% of the recruited 
cells were positive for GLUT1 (figure 4G). The percentage of 
GLUT1- positive cells was also correlated with the inflammatory 
response and glucose uptake measured by IL-1β concentration 
and SUVmax, respectively, in the air pouch (figure 4H1). Finally, 
we validated these in vivo data by GLUT1 expression analysis on 
inflammatory cells isolated from gout flare patients. We observed 
that the ratio of GLUT1- expressing cells among the neutro-
phils was higher in the synovial fluid than in blood (figure 4J), 
suggesting that cells increased their GLUT1 expression at the site 
of inflammation where MSU crystals are present (MSU crystals 
were observed in 100% of the synovial fluid samples).
Altogether, these results suggested that MSU and m- CPPD 
crystal inflammation is supported by a de novo increase in 
GLUT1 expression and its relocalisation to the plasma membrane, 
required for glucose uptake and metabolic reprogramming.
GLUT1 regulates crystal-induced inflammation
To assess the role of GLUT1 in MSU and m- CPPD crystal- 
induced inflammation, we adopted pharmacological (STF-
31: iGLUT1) and genetic knock- down approaches (SLC2A1 
small interfering RNA: siGLUT1; see validation in figure 5A) 
of GLUT1 inhibition. First, iGLUT1 suppressed the glucose 
Figure 4 MSU and m- CPPD crystals increase GLUT1 expression at the cell plasma membrane. (A–C) GLUT1 membrane localisation in primed- THP-1 
cells stimulated by PBS, MSU or m- CPPD was assessed by immunofluorescence confocal microscopy. (A) Imaging representative of five experiments 
and (B) quantification of GLUT1 membrane expression. (C) Representative overlay (MFI) by FACS of GLUT1 cell surface expression, (D) quantification 
of the ratio of GLUT1 MFI (crystal over PBS, LPS used as a positive control of stimulation) (n=5). Kruskal- Wallis test with FDR correction (*): *p<0.05, 
**p<0.01, ***p<0.001. (E–I) GLUT1 expression was evaluated in mouse air pouch model of microcrystal inflammation. After PBS, MSU or m- CPPD 
injection (E) GLUT1 expression in the air pouch membranes was assessed by immunofluorescence confocal microscopy (representative images (n=5), 
(F) expression of GLUT1 gene was assessed by RT- qPCR using RNA isolated from infiltrated cells collected in air pouch lavages. Data are represented
as a % of GLUT1 or GLUT6 mRNA expression compared with 18S mRNA expression in each condition of stimulation. (n=6). (G) Percentage of GLUT1- 
expressing cells was assessed by FACS using infiltrated cells collected in air pouch lavages (n=6). Kruskal- Wallis test with FDR correction (*): *p<0.05, 
**p<0.01, ***p<0.001. Correlation between GLUT1- positive cells in the air pouch lavages and (H) IL-1β production or (I) glucose uptake, Spearman
test. (J) Plasma membrane expression of GLUT1 was evaluated FACS comparing neutrophils isolated from flaring joint and circulating neutrophils
isolated from peripheral blood of the same patient at the same moment (n=7). Two- tailed paired t test (*): *p<0.05, **p<0.01, ***p<0.001. FACS, 
fluorescence activated cell sorting; GLUT1, glucose transporter 1; IL, interleukin; LPS, lipopolysaccharide; m- CPPD, monoclinic calcium pyrophosphate
dihydrate; MFI, mean fluorescence intensity; mRNA, messenger RNA; MSU, monosodium urate; SUVmax, maximum standardised uptake value.
uptake induced by MSU and m- CPPD crystals (figure 5B), posi-
tioning GLUT1 as the main GLUT involved in the microcrystal 
response. Then, we demonstrated that GLUT1 inhibition by 
either of the two technical approaches led to a 50% inhibi-
tion of IL-1β production in response to MSU and m- CPPD 
(figure 5C,D). This IL-1β reduction under iGLUT1 was due 
to an inhibition of the NLRP3 inflammasome activation as 
GLUT1 inhibition prevented by 75% the ASC speck formation 
(figure 5E). Partial inhibition of NLRP3 activation and subse-
quently IL-1β production by iGLUT1 suggested that GLUT1 
was involved in an amplification loop but not an initial signal 
of IL-1β production. Nevertheless, we observed that glucose 
depletion and GLUT1 inhibition decreased both NLRP3 
and IL-1β gene expression and pro- IL-1β synthesis induced 
by phorbol myristate acetate (PMA) priming, suggesting that 
glucose also played a role in the first signal (see online supple-
mentary figure S5A,B).
Finally, we evaluated the iGLUT1 efficiency on microcrystal 
inflammation in vivo. iGLUT1 delivered by intraperitoneal 
injection allowed to drastically inhibit all signs of local inflam-
mation induced by MSU and m- CPPD into the air pouch, 
namely, a decrease in IL-1β production (figure 5G), a reduc-
tion of cell infiltration (figure 5H) associated with neutrophil 
recruitment (see online supplementary figure S5C,D) and a 
global alleviation of the inflammatory score observed from HE 
staining of air pouch membrane (figure 5I).
DISCUSSION
We found that MSU and m- CPPD crystal- induced macro-
phage production of IL-1β, which orchestrated the recurrent 
Figure 5 GLUT1 drives crystal- induced inflammation. (A–F) PBS, MSU or m- CPPD crystal stimulation of primed THP-1 cells pretreated or not (PBS) 
with STF-31 (20 µM, iGLUT1) or transfected with GLUT1 siRNA (si). (A) Validation of GLUT1 expression knock- down by western blot, (B) Quantification 
of [18F]-FDG in the cell pellets. Data shown as fold change after crystal stimulation compared with PBS. (C,D) IL-1β concentration measured by 
ELISA in the supernatants of cell culture (n=3). (D) Data are presented as % of inhibition compared with wild type THP-1 cells (n=3). (E,F) ASC speck 
formation was assessed by immunofluorescence confocal microscopy. (E) Imaging representative of four experiments. (F) Quantification of cells 
showing at least one ASC speck formation. Kruskal- Wallis test with FDR correction (*): *p<0.05, **p<0.01, ***p<0.001. (G–J) On air pouch model 
of crystal inflammation in mice treated or not with GLUT1 inhibitor STF-31 (iGLUT1, 10 mg/kg). (G) IL-1β concentration quantified by ELISA and 
(H) number of infiltrate cells in air pouch lavages (n=15 per group). H&E staining (PBS: n=8 mice per group, iGLUT1: n=5 mice per group) realised
on air pouch membrane sections. (I) Representative images and (J) scoring of inflammation. Two- way analysis of variance test with FDR correction
(*): *p<0.05, **p<0.01, ***p<0.001. [18F]-FDG, 18F- fluorodeoxyglucose; ASC, apoptosis- associated speck- like containing a CARD; GLUT1, glucose
transporter 1; IL, interleukin; m- CPPD, monoclinic calcium pyrophosphate dihydrate; MSU, monosodium urate; NS, not significant.
inflammatory flares in gout and m- CPPD deposition disease, 
respectively, relied on glucose uptake through GLUT1 (figure 6). 
Glucose deprivation and glycolysis inhibition decreased NLRP3 
and IL-1β gene expression and suppressed ASC speck formation 
(ie, NLRP3 activation), IL-1β production and neutrophil infil-
tration induced by MSU and m- CPPD crystals. Crystals induced 
GLUT1 de novo expression and its localisation to plasma 
membrane, along with gene expression of enzymes involved in 
glycolysis such as HK-2. Increase glucose uptake during MSU 
and m- CPPD crystal- induced inflammation has been reported 
in patients using [18F]-FDG PET/CT.18 19 We reproduced these 
observations in a mouse model, and we identified for the 
first time the key role of GLUT1 in both MSU and m- CPPD 
crystal- induced inflammation in mice and in human samples 
harvested during gout flare. Interestingly, we discovered that 
MSU crystal- induced glucose uptake favoured glycolytic activity, 
while m- CPPD crystals induced glucose uptake without modu-
lation of glycolytic activity. Surprisingly, both microcrystals did 
not modulate OXPHOS. These results were distinct from the 
Warburg effect described in cancer cells and LPS- stimulated 
macrophages, where metabolic switch enhanced aerobic glycol-
ysis at the expense of mitochondrial respiration.8–10 12 26 Also 
reported, MSU crystals increased both OXPHOS and glyco-
lytic activity on human neutrophils.27 These findings further 
supported the complexity of cellular metabolic programmes 
and responses, which varied with the type and concentration of 
stimuli, cell type and cell species and tissue environment.13 28–30 
For example, LPS stimulated Warburg- like metabolic repro-
gramming in human monocytes at concentrations between 1 
and 100 ng/mL but increased OXPHOS at a low dose of 0.1 ng/
mL.29 Likewise, monocytes stimulated with TLR2 agonist 
Pam3CysSK4 (P3C) or by whole microorganisms activated both 
glycolysis pathway and OXPHOS.29 Finally, analysis of monocyte 
transcriptomic responses under 28 different stimuli identified 10 
clusters that represented distinct activation states with distinct 
metabolic responses.30 These data suggested that a specific 
stimulus would trigger metabolic responses corresponding to a 
specific and functional requirement of the cells. For instance, 
MSU and m- CPPD crystal- induced metabolic reprogramming 
might increase either the phagocytosis capacity (as shown in 
monocytes stimulated by P3C) or the reactive oxygen species 
(ROS) production (as shown in neutrophils stimulated by MSU 
crystals),27 29 two well- known mechanisms of crystal- induced 
NLRP3 activation.1 31 In parallel, we found that MSU crystals 
activated macrophage glycolysis pathway to produce IL-1β as 
well described in macrophages stimulated by LPS, in activated 
T cells and cancer cells.8–10 12 17 26 28 However, how MSU- 
induced and m- CPPD crystal- induced glucose uptake activates 
the NLRP3 inflammasome remained unknown. One explanation 
could come from the induction of HK-2 by MSU and m- CPPD. 
Indeed, in LPS- stimulated macrophages, IL-1β production 
can be modulated by metabolites and enzymes involved in the 
glycolysis pathway, including HK-1 and HK-2, which can both 
interact with mitochondrial voltage- dependent anion channel to 
activate NRLP3,32 glyceraldehyde 3- phosphate dehydrogenase33 
and inactive PKM2.14 34 Cancer cells and LPS- stimulated macro-
phages overexpress inactive dimer PKM2, which promotes 
HIF-1α activation and transcription of HIF-1α-dependent 
genes, including IL-1β and glycolytic enzymes.14 34 Alternatively, 
MSU and m- CPPD crystal- induced glucose uptake might stim-
ulate IL-1β production through Akt pathway and ROS produc-
tion.27 35 36 PI3K (phosphatidylinositol-3 kinase)/Akt pathway is 
commonly activated by MSU and m- CPPD crystals.27 36 37 Akt 
activation enhanced IL-1β production through induction of 
ROS and glucose metabolism. Akt promoted glycolysis through 
stimulation of HK-2 and glucose uptake via translocation of 
GLUT1 to cell surface membrane and activation of its down-
stream mTORC1. This later stimulated HIF-1α, which enhanced 
expression of genes involved in glycolytic reprogramming, such 
as SLC2A1 (GLUT1).38
Glucose is a critical nutrient component for inflammatory 
macrophages, and GLUT1 is the main GLUT expressed in 
LPS- stimulated macrophages.24 Elevated GLUT1 expression 
increased glucose metabolism and glycolysis, ROS produc-
tion and expression of proinflammatory mediators, including 
IL-1β.24 Here, we found that MSU and m- CPPD crystals trig-
gered plasma membrane localisation of GLUT1, which drove 
glucose uptake, NLRP3 activation and IL-1β production. 
Furthermore, we observed in gouty patients that GLUT1 was 
more frequently expressed at the surface of neutrophils isolated 
from flaring joint than neutrophils isolated from peripheral 
blood of the same patient. These results added crystal- induced 
IL-1β production to the list of inflammatory conditions regu-
lated by GLUT1- induced glucose uptake in macrophages, 
such as cancer, infection, autoimmune disease, diabetes and 
obesity.14 24 28 35 39 40 Interestingly GLUT1 also governed post-
prandial glucose uptake by peritoneal macrophages, leading 
to IL-1β production and, subsequently, insulin secretion.35 
This might explain why gout flare frequently occurred after 
a feast. MSU and m- CPPD crystals enhanced both GLUT1 
mRNA expression and GLUT1 plasma membrane localisa-
tion by unknown mechanisms. GLUT1 activity is regulated by 
its membrane localisation and activation, kinetic of its inter-
nalisation, endosomal sorting and recycling back to the cell 
membrane, which depends on retromer cargo complex.41 42 
Cancer cells favour aerobic glycolysis by promoting GLUT1 
plasma membrane localisation through the PI3K/Akt/mTORC 
Figure 6 GLUT1 and glycolysis regulate NLRP3 inflammasome 
activation and IL-1β production induced by MSU and m- CPPD crystals. 
Crystals induced GLUT1 gene expression, GLUT1 production and 
its localisation in plasma membrane. NLRP3 activation and IL-1β 
production in response to MSU and m- CPPD crystals rely on glucose 
uptake through GLUT1 and glycolysis. In parallel, MSU and m- CPPD 
crystals induce gene expression of pro- IL-1β and NLRP3, along with 
enzymes involved in glycolysis and TCA pathways, including GLUT1, 
HK-2, MCT, PDP1 and PDK1/2. ECAR, extracellular acidification rate; 
GLUT1, glucose transporter 1; HK, hexokinase; IL, interleukin; m- CPPD, 
monoclinic calcium pyrophosphate dihydrate; MCP, mitochondrial 
carrier proteins; MCT, monocarboxylate transporter; PDP, pyruvate 
dehydrogenase phosphatase; PDK, pyruvate dehydrogenase kinase. TCA, 
tricarboxylic acid.
pathway.43–45 Akt activation promotes cell surface membrane 
recycling of GLUT1 and reduces its internalisation.43 Inversely, 
Akt inhibition by phosphatase TENsin homologue deleted on 
chromosome 10 (PTEN) prevented GLUT1 plasma membrane 
localisation45–47 Whether MSU and m- CPPD crystals regu-
lated GLUT1 membrane expression through the Akt pathway 
needs to be studied. Alternatively, MSU and m- CPPD crys-
tals might induce GLUT1 membrane localisation through 
thioredoxin- interacting protein, which facilitated GLUT1 
endocytosis via clathrin- coated pits, modulated PTEN activity 
and was involved in crystal- induced inflammation.31 48 Lastly, 
crystal- induced glucose uptake might be due to an increase 
in GLUT1 transport activity. Indeed, the drastic decrease of 
cytosolic ATP observed after MSU and m- CPPD crystal stimu-
lation might stimulate GLUT1 transport activity, as previously 
reported.49 50
Although SLC2A6 (GLUT6) gene expression in THP-1 cells 
was highly enhanced by either MSU or m- CPPD crystal stim-
ulation, its exact role in crystal- induced inflammation and 
glucose uptake is currently unknown. Recent data suggested that 
GLUT6 was involved in neither glucose uptake nor glycolysis 
nor OXPHOS.25 51 52 GLUT6- deficient mice had normal glucose 
metabolism51 and GLUT6- deficient BMDMs had similar ECAR 
and OCR than wild- type cells.25 52 Moreover, expression of proin-
flammatory mediators such as IL-1β and TNF-α was unchanged in 
the absence of GLUT6.52 Further studies are needed to understand 
how GLUT6 participates to crystal- induced inflammation.
How MSU and m- CPPD crystals induced GLUT1 membrane 
localisation constituted the main limitation of our study. 
Although we did not identify the exact mechanisms involved 
in crystal effects, our results suggested that MSU and m- CPPD 
crystals increased, in THP-1 and mouse BMDM cells, GLUT1 
gene expression, GLUT1 protein production and membrane 
location and GLUT1 activity. Whether crystals induced IL-1β 
production by primary human monocytes does also depend 
on glucose uptake need specific studies. Similarly, we did not 
assess in this study how hyperglycaemic modulated crystal- 
induced inflammation in vivo. We planned to address this 
question in type 2 and type 1 diabetes using Ob/Ob mice 
and streptozotocin mouse models, respectively. Interestingly, 
recent report supported our findings by showing that patients 
treated with metformin had less gout flare.53 Finally, metabolic 
reprogramming during gout flare needed also to be confirmed 
in patients by doing metabolomics analysis in neutrophils 
isolated from inflamed joint.
Overall, metabolic changes characterised by GLUT1- 
mediated glucose uptake and increase in glycolysis governed 
MSU and m- CPPD crystal- activated IL-1β production. These 
findings open new therapeutic paths to modulate crystal- 
related inflammation.
MATERIALS AND METHODS
See a fully detailed Materials and methods in the online supple-
mentary file.
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